At Nanomedical Diagnostics, our goal is to help you fully characterize and explore your biomolecules to make better decisions earlier. We have developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that makes label-free kinetic binding and affinity data accessible to all researchers. Unique graphene biosensors at the heart of the assay deliver highly-sensitive kinetic characterization of small molecules ≥10 Da in complex samples from solvents and detergents to cell fractions and tissue lysate. With an unprecedented 11-log dynamic range and the ability to detect with a minuscule amount of sample, the platform is a unique orthogonal technology to accelerate drug discovery.
As the world’s leading mass-manufacturer of next-generation graphene biosensors, our mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and portable diagnostic and health monitoring platforms. Our next system, Agile R200, will support over 20,000 measurements an hour when implemented with a 1536-well plate design configuration and combined with standard automated liquid handlers. It will provide kinetic characterization in an initial high-throughput screen, and is slated to launch in 2018.